We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc | LSE:0R2M | London | Ordinary Share | REGENERON PHARMACEUTICALS ORD SHS |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 296.60 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 13.12B | 3.95B | 36.9050 | 27.44 | 31.77B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 20:46:20 | O | 1 | 76,851.71 | USD |
| Date | Time | Source | Headline |
|---|---|---|---|
| 09/7/2024 | 06:11 | ALNC |  IN BRIEF: Regeneron says second quarter results to include R&D charge |
| 03/7/2024 | 10:46 | ALNC | EU approves Sanofi drug Dupixent for chronic lung disease |
| 26/1/2024 | 21:07 | ALNC | Sanofi and Regeneron celebrate Dupixent's FDA approval |
| 11/12/2023 | 19:25 | ALNC | Leading pharmaceutical firms highlight positive trial data on lymphoma |
Regeneron Pharmaceuticals (0R2M) Share Charts1 Year Regeneron Pharmaceuticals Chart |
|
1 Month Regeneron Pharmaceuticals Chart |
Intraday Regeneron Pharmaceuticals Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 06:16:02 | 76,851.71 | 1 | 0.00 | O |
| 05:32:43 | 1,013.91 | 5 | 0.00 | O |
| 05:32:43 | 77,241.97 | 5 | 0.00 | O |
| 05:25:37 | 1,011.40 | 50 | 0.00 | O |
| 05:12:47 | 1,012.25 | 1 | 0.00 | O |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
